Condition: Eosinophilic Esophagitis · Sponsor: Dr. Falk Pharma GmbH
The purpose of this study is to prove the non-inferiority of a 6-weeks treatment with 1 mg budesonide orodispersible tablets BID versus 2 mg budesonide orodispesible tabletss for the induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis.
This description comes directly from the study's public registry record.
Sarah Burrack, Dr. · 004976115140 · zentrale@drfalkpharma.de
Always discuss trial participation with your own doctor first.
| Dr. Falk Investigational Site | Scottsdale, Arizona, United States | Recruiting |
| Dr. Falk Investigational Site | Little Rock, Arkansas, United States | Recruiting |
| Dr. Falk Investigational Site | La Jolla, California, United States | Recruiting |
| Dr. Falk Investigational Site | Lomita, California, United States | Withdrawn |
| Dr. Falk Investigational Site | San Diego, California, United States | Recruiting |
| Dr. Falk Investigational Site | Doral, Florida, United States | Recruiting |
| Dr. Falk Investigational Site | New Port Richey, Florida, United States | Recruiting |
| Dr. Falk Investigational Site | Boise, Idaho, United States | Recruiting |
| Dr. Falk Investigational Site | Houma, Louisiana, United States | Withdrawn |
| Dr. Falk Investigational Site | Marrero, Louisiana, United States | Withdrawn |
| Dr. Falk Investigational Site | Boston, Massachusetts, United States | Recruiting |
| Wyoming | Ann Arbor, Michigan, United States | Recruiting |
+ 15 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06596252